Sight Diagnostics

Sight Diagnostics

Pathology & Laboratory Diagnostics

About Sight Diagnostics

Sight Diagnostics is pioneering a new generation of immune signatures by decoding live immune cells in action. The company combines exclusive proprietary data with cutting-edge artificial intelligence to deliver unprecedented clinical insights in the field of pathology and laboratory diagnostics. Sight's innovative approach focuses on analyzing immune cell behavior in real-time, enabling more accurate and comprehensive diagnostic capabilities. The company's technology platform represents a significant advancement in understanding immune system function and disease states. Led by CEO Nitsan Maayan-Rabinowich, CTO Ben Leshem PhD, and Chief Product & Clinical Officer Asi Cohen-Dotan PhD, Sight has gained recognition as a disruptor in the healthcare technology space. The company has been honored with multiple awards including recognition in CNBC's 2021 Disruptor 50 Companies list and Fast Company's 2021 World Changing Ideas Award. Sight's mission is to push the boundaries of innovation in diagnostic medicine, providing healthcare providers with advanced tools to better understand and monitor immune system health and function.

Mission & Story

Mission

Pushing the Boundaries of Innovation

Clinical Focus

Medical conditions and clinical areas addressed by Sight Diagnostics.

immune system disordersimmune cell analysis

Who It Serves

Healthcare ProvidersClinical Laboratories

Milestones & Awards

Recent Milestones

Recognition as CNBC 2021 Disruptor 50 Company, Fast Company 2021 World Changing Ideas Award

Awards & Recognition

2021 CNBC Disruptor 50 Companies, 2021 Bronze Winner, 2021 World Changing Ideas Award Honorable Mention, 2020 UCSF Digital Health Awards Quarterfinalist

Company Details

Work here?

Claim this listing to update company information and connect with our audience.

Claim This Listing

Official Sources

Last updated Jul 1, 2026

Similar Companies in this Market

View all 45
Aiforia

Aiforia

Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.

Aignostics

Aignostics

Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.

Aiosyn

Aiosyn

Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.

AIxMed

AIxMed

AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.

Akoya Biosciences

Akoya Biosciences

Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.

Caris Life Sciences

Caris Life Sciences

Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.

CellaVision

CellaVision

201-500 employees

CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.

Clever Culture Systems

Clever Culture Systems

Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.

Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.